Resultados del estudio clínico de fase I del anticuerpo bifuncional PD-1/CTLA-4 de Qilu Pharma ...Middle East

PR Newswire - News
Resultados del estudio clínico de fase I del anticuerpo bifuncional PD-1/CTLA-4 de Qilu Pharma
-Resultados del estudio clínico de fase I del anticuerpo bifuncional PD-1/CTLA-4 Iparomlimab/Tuvonralimab de Qilu Pharma publicado en línea en Journal of Hematology & Oncology JINAN, China, 12 de mayo de 2023 /PRNewswire/ -- El 8 de mayo de 2023, Journal of Hematology & Oncology (JHO,...

Hence then, the article about resultados del estudio clinico de fase i del anticuerpo bifuncional pd 1 ctla 4 de qilu pharma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Resultados del estudio clínico de fase I del anticuerpo bifuncional PD-1/CTLA-4 de Qilu Pharma )

Apple Storegoogle play

Last updated :

Also on site :



Latest News